Potential Reduced Exposure Products for Tobacco Users: What Do We Need to Know, What Do We Know, and How do We Get There From Here? Thomas Eissenberg,

Slides:

Advertisements

Similar presentations

2008 Johns Hopkins Bloomberg School of Public Health Setting Up a Smoking Cessation Clinic Sophia Chan PhD, MPH, RN, RSCN Department of Nursing Studies.

Advertisements

 2007 Johns Hopkins Bloomberg School of Public Health Section B Non-Combusting Products and Oral Products.

New Tobacco Products: Harm Reduction or Harm Induction? Herbert H. Severson Senior Research Scientist Oregon Research Institute Eugene, Oregon.

1. Initiated Act 1 Fall Initiated Act Allocation of MSA Funds 3.

Reducing the toll of smoking-related disease and death: The case for tobacco harm reduction The rationale for establishing low-toxicity smokeless nicotine.

Tobacco & Cancer. Tobacco Use And Cancer Tobacco use, the most preventable cause of death in our society, accounts for at least 30% of all cancer deaths.

UNIVERSITY OF MARYLAND SCHOOL OF LAW The Basis of a Comprehensive Regulatory Policy for Reduced Harm Tobacco Products David Sweanor, Adjunct Professor.

In the name of GOD Decreasing smoking behavior and risk through CYP2A6 inhibition Shadi Sarahroodi (Pharm.D) Ahvaz Jondishapour University of medical.

Chapter 20: The Effects of Tobacco Use. Key Terms  Nicotine  Stimulant  Carcinogen  Tar  Carbon Monoxide  Smokeless Tobacco  Leukoplakia  Nicotine.

The Health Implications of Raising the Minimum Age for Purchasing Tobacco Products Eric N. Lindblom Director, Office of Policy Center for Tobacco Products,

09-Sep-2003 Predicting human risk with animal research: lessons learned from caffeine/ephedrine combinations Richard J. Briscoe, Ph.D. Safety Pharmacology.

Tobacco Lesson 1. Tobacco has ____________ effects on almost all body systems. cigarette lungs cancer tobacco harmful crave oxygen.

History of Tobacco Control in the United States Kristie L. Foley, Ph.D. Associate Professor of Medical Humanities Davidson College Szeged, Hungary 18 June.

Information on tobacco packages could encourage and help tobacco users to stop using tobacco or find least possible harmful ways of use for those unable.

Substance abuse refers to the continued use of the substance despite knowing problems associated with the substance such as persistent desire to use it.

Prevention strategies

Tobacco Chapter 8 ???? ____ % of new smokers are adolescents/teenagers ???? Smokers have about a _____% greater risk of dying from coronary heart disease.

 2011 Johns Hopkins Bloomberg School of Public Health Regulation of Tobacco Products Mitch Zeller, JD Pinney Associates.

Canadian E-cigarette Regulation Presentation by Reza B.

Greens MyLifeForceBalance.com These statements has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any.

Electronic cigarettes (e-cigarettes) are battery operated devices that resemble the appearance of a cigarette and produce a warm vapor when withdrawn from.

Kenneth E. Warner University of Michigan University of Iowa November 15, 2002 Technology, Policy, and the Future of Nicotine Addiction.

Current challenges in tobacco prevention – do new products pose threats or opportunities? Lars M. Ramström Institute for Tobacco Studies Stockholm, Sweden.

Our Global Harm Reduction Programme TMA 2009 David O’Reilly, PhD Head of Public Health & Scientific Affairs © British-American Tobacco (Holdings) Limited.

Welcome to the Beat the Pack Program Program Launch: Reasons to Quit.

20th Century World War 1 (soldier’s relief) 1920’s beginning of heavy marketing World War II Marlboro Man 1964 Smoking linked to cancer 1971 advertisements.

Evidence-based/Best Practices Tobacco Control Hadii Mamudu, PhD, MPA COPH-China Institute November 17, 2011.

Quittin’ Time: Helping Employees Become Tobacco-free June 2005.

Snus as a Substitution for Smoking: The Swedish Experience Lars M. Ramström Institute for tobacco studies Stockholm, Sweden.

 2007 Johns Hopkins Bloomberg School of Public Health Tobacco Control Surveillance Benjamin Apelberg, PhD, MHS Institute for Global Tobacco Control Johns.

Le rôle de la réduction de dommages dans la lutte antitabac The role of harm reduction in tobacco control Lars M. Ramström Institute for Tobacco Studies.

Dreams become reality - success with tobacco control means success with cancer control Christopher Squier College of Dentistry University of Iowa.

Characteristics of new tobacco products emerging on the tobacco market: implications for tobacco control policies Lars M. Ramström Institute for Tobacco.

Smoking cessation aided by low-toxicity smokeless tobacco can save many lives Lars M. Ramström Institute for Tobacco Studies Täby, Sweden UKNSCC 2014 Thursday.

Tobacco Harm Reduction: Perspectives of the Tobacco Control Community Kenneth E. Warner, Ph.D. Erika G. Martin University of Michigan School of Public.

Lung Cancer Molecular Pathology of Cancer Boot Camp January 4, 2012 Jennifer Rider, ScD.

Number of deaths (’000s) in 1998 attributable to tobacco use WHO Region Males Females World Health Report 1999 All member states3, Africa 112.

FORMS of TOBACCO. Cigarettes Smokeless tobacco (chewing tobacco, oral snuff) Pipes Cigars Clove cigarettes Bidis Hookah (waterpipe smoking) Image courtesy.

FORMS of TOBACCO This module focuses on different forms of tobacco that are available in the U.S.

 2007 Johns Hopkins Bloomberg School of Public Health Section B Tracking Tobacco-Related Death and Disease.

The Importance of Research in Tobacco Control Jeffrey Koplan, MD, MPH Emory Global Health Institute- China Tobacco Control Partnership.

Cutting tobacco’s death toll − an overview of different options Lars M. Ramström Institute for Tobacco Studies Stockholm, Sweden 5th Annual Conference.

“Analytical Tools and Data Collection” April 2009 EuropeAid/125317/D/SER/TR Session 1 Introduction to Role of Impacts Assessment in RIAs.

Early interest focused on pseudo-cigarettes. Why? Fascination with high-tech products First “splash” (Premier, mid-1980s) Promised large decreases in a.

The Role of Harm Reduction in Tobacco control – An Update of Pros and Cons Lars M. Ramström Institute for Tobacco Studies Stockholm, Sweden 53rd International.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for Health Statistics Occupational exposure to.

 Tobacco is a product prepared from the leaves of the tobacco plant.  It is smoked in cigarettes, cigars, pipes and consumed as snuff, chewing tobacco.

Policies for helping smokers who cannot quit: a prerequisite for maximum prevention of tobacco induced diseases Lars M. Ramström Institute for Tobacco.

FDA Regulation of Tobacco Washington, DC October 21, 2015 What is Relative Risk-a look at the Continuum of Harm Aruni Bhatnagar, PhD, Professor, University.

FDA Regulation: The Impact on Product Development and Reporting Monica Graves Director – Marketing Operations Oversight RAI Services Company May 18, 2009.

Wellness Chapter 20 Tobacco Lesson One The Health Risks of Tobacco Use.

Learning from others California Massachusetts Other States CDC.

By: Sherry Hargrove Core: 1 Science. I decided to do my project on tobacco smoke and the chemicals found in it. Also I wanted to tell of the harms tobacco.

FDA Advisory Committee Tobacco Constituents Subcommittee June 8 & 9, 2010 Gaithersburg, Maryland Recommendations for Measurement of Toxic Tobacco Constituents.

(c) 2005 The McGraw-Hill Companies, Inc. All rights reserved. Chapter Nine: Rejecting Tobacco Use.

Caroline O. Cobb, Ph.D. VCU Psychology Department & Center for the Study of Tobacco Products Vaping & Students: Who’s Puffing What?

Tobacco. Nicotine is a stimulant drug found in tobacco products, including cigarettes, clove cigarettes, cigars, chewing tobacco, pipe tobacco, and snuff.

Eliminate Quitline Iowa About 87,800 fewer tobacco users who would successfully quit At least $1.2 BILLION in excess future healthcare costs – At least.

Strategies for regulation of cigarette emissions The WHO product regulatory approach Nigel Gray David Burns For TobReg Working Group 1 in Conjunction with.

E - CIGARETTES: WHAT’S THE REAL MEDICAL INNOVATION BREAKTHROUGH? Dr Kevin Bridgman - Chief Medical Officer & Director Nicovations is a wholly owned subsidiary.

Potential Reduced Exposure Products (PREPs) for Tobacco Users: What Are They and What Do They Do ? Thomas Eissenberg, Ph.D. Department of Psychology and.

Charles Gardner, MD, CCFP, MHSc, FRCPC Medical Officer of Health Simcoe Muskoka District Health Unit October, 2016.

screening, brief intervention, and referral to treatment

Chapter 20 Tobacco.

EU tobacco and nicotine regulations - general aspects

Electronic Cigarettes – What nurses need to know

The Burden of Tobacco Use

Griffith Health Institute

Chapter 8 review.

Purposes of a Tobacco-Related Surveillance System

Presentation transcript:

Potential Reduced Exposure Products for Tobacco Users: What Do We Need to Know, What Do We Know, and How do We Get There From Here? Thomas Eissenberg, Ph.D. Department of Psychology and Institute for Drug and Alcohol Studies VCU Supported by NIH DA11082, DA06052, DA07027, RWJF’s Tobacco Etiology Research Network, VCU’s IDAS and Dept. of Pharm/Tox, VCU’s NCI-supported Massey Cancer Center

Topics to cover. What PREPs are currently available for tobacco users? What do we need to know about these PREPs? What do we know now? How do we get there from here?

What PREPs are currently available? Cigarette-like PREPs for smokers: - RJR’s Eclipse ® – reduces carcinogenic compounds? - PM’s Accord ® – reduces secondhand smoke? - B&W’s Advance™ – reduces nitrosamine exposure? - Vector’s Omni™ – reduces PAHs, nitrosamines, catechols? - Vector’s Quest™ – reduces nicotine exposure? Oral PREPs for smokers intended to provide tobacco exposure when/where smoking is forbidden (Ariva™, Exalt™, Revel™). Oral PREPs for smokeless tobacco users: - Star’s Stonewall™ – reduces nitrosamine exposure? - Small label products (“Bacc-off”) – reduces nicotine exposure? - Swedish “snus” products – reduces carcinogen exposure?

What do we need to know about these PREPs? At a minimum: Will they perform as advertised? More importantly: Will they decrease tobacco-related death and disease in today’s tobacco users? Especially: Will any PREP-associated reduction in health risk be offset by: - Increased prevalence tobacco use initiation. - Decreased prevalence of tobacco use cessation.

Problem and Question: Problem: PREPs are marketed now, but establishing PREP effects on death and disease may take decades. Question: Can we use limited information now to predict PREP effects in the future? - Using scientific methods that are objective, rigorous, and transdisciplinary (combining basic and clinical research). - Decisions that are made within a regulated environment.

Despite advertising claims and widespread acceptance, previous PREPs (“low-yield” cigarettes) failed to decrease death and disease (Samet, 1996; Thun et al., 1995). Failure attributable to human/cigarette interaction: - Smokers block vent holes (Kozlowski et al., 1988). - Alter smoking style (more/bigger puffs; Baldinger et al., 1995). Machine testing fails to capture effects of human/cig interaction. What do we know: “PREP History 101”.

Lessons learned from “PREP History 101”. Evaluating PREPs involves measuring PREP users’: - Exposure to toxicants, because, for example, machine- smoking yield (e.g., FTC) does not predict what a smoker receives. - Behavior, to assess product-induced behavioral changes. - Effects of use, including withdrawal suppression. This information: - Can be used to test product claims. - May be valuable in predicting effects on death and disease. Some of this work has already started, especially with cigarette- like PREPs.

* Plasma nicotine (ng/ml) * * Eclipse ® Own Accord ® What we know about Eclipse ® and Accord ®. Data from Breland et al., 2002a 90 Post 2.5-hour session Pre 2.5-hour session * * * Expired air CO (ppm)   Own Eclipse ® Accord ® Eclipse ® Withdrawal Score Own * * *  Accord ®  

What we know about Advance™ -- I pre 2.5-hour session post 2.5-hour session Expired air CO (ppm) Own * * Advance™  Plasma nicotine (ng/ml) * Own * Advance™  Withdrawal score Own Advance™ * * Data from Breland et al., 2002b

What we know about Advance™ -- II NNAL (pg/ml) Day No Smoking Own Brand Advance TM     Data from Breland et al., 2003

Conclusions: Accord ®, Eclipse ®, and Advance™ Relative to normally marketed cigarettes: - Eclipse ® Delivers less nicotine; suppresses withdrawal fully. × Delivers about 30% more CO. - Accord ® Delivers less nicotine and CO. × Suppresses withdrawal inadequately. - Advance ™ Delivers less CO; less NNK; suppresses withdrawal. × Delivers more nicotine in lab. Based on these results: - Some marketing claims substantiated; - Reduction in CO and/or NNK may be relevant to harm reduction.

Other PREPs. Cigarette-like PREPs for smokers: - Omni™ – Delivers about 20% less NNK and 5% pyrene than normally marketed brands (Hatsukami et al., submitted) - Quest™ – Delivers less nicotine. Oral PREPs for smokers: no data available. May represent exposure increase. Oral PREPs for SLT users: - Stonewall™ – No data available. - Small label products – Some deliver no measurable nicotine. - Swedish “snus” products – Delivers about 50% NNK than U.S. brands (Hatsukami et al., submitted).

How do we get there from here? Much work needed. Will they perform as advertised? - Exposure reduction can (and should) be tested now. - Unsubstantiated claims must not be allowed. Will they decrease tobacco-related death and disease in today’s tobacco users? - Restrict marketing until rigorous, objective data can be used to make reasonable hypotheses regarding harm reduction. - Implement post-marketing surveillance to test hypotheses. Will any PREP-associated reduction in health risk be offset by increased initiation/decreased cessation: methods development needed.

Why PREP evaluation is needed now. Source: Dr. Ken Warner.